Journals International Journal of Neuro...

International Journal of Neuropsychopharmacology
María Hidalgo-Figueroa, Alejandro Salazar, Cristina Romero-López-Alberca, Karina S MacDowell, Borja Garcia-Bueno, Miquel Bioque, Miquel Bernardo, Mara Parellada, Ana Gonzalez-Pinto, M Paz Garcia-Portilla, Antonio Lobo, Roberto Rodriguez-Jiménez, Esther Berrocoso, Juan C Leza
BACKGROUND: The clinical debut of schizophrenia is frequently a first episode of psychosis (FEP). As such, there is considerable interest in identifying associations between biological markers and clinical or cognitive characteristics that help predict the progression and outcome of FEP patients. Previous studies showed that high prolactin, low oxytocin and high homocysteine are factors associated with FEP 6 months after diagnosis, at which point plasma levels were correlated with some clinical and cognitive characteristics...
August 21, 2023: International Journal of Neuropsychopharmacology
Jian-Bin Ge, Bo Jiang, Tian-Shun Shi, Wei-Yu Li, Wei-Jia Chen, Bao-Lun Zhu, Zheng-Hong Qin
BACKGROUND: Although depression has been a serious neuropsychiatric disorder worldwide, current antidepressants used in clinical practice have various weaknesses including delayed onset and low rates of efficacy. Recently, the development of new antidepressants from natural herbal medicine has become one of the important research hotspots. Cucurbitacin B is a natural compound widely distributed in the Cucurbitaceae and Cruciferae families and has many pharmacological activities. The present study aimed to investigate whether cucurbitacin B possess antidepressant-like effects in mice...
August 21, 2023: International Journal of Neuropsychopharmacology
Xue Dong, Simon Zhornitsky, Wuyi Wang, Thang M Le, Yu Chen, Shefali Chaudhary, Chiang-Shan R Li, Sheng Zhang
BACKGROUND: Previous studies have focused on both ventral striatum (VS) and dorsal striatum (DS) in characterizing dopaminergic deficits in addiction. Animal studies suggest VS and DS dysfunction each in association with impulsive and compulsive cocaine use during early and later stages of addiction. However, few human studies have aimed to distinguish the roles of VS and DS dysfunction in cocaine misuse. METHODS: We examined VS and DS resting-state functional connectivity (rsFC) of 122 recently abstinent cocaine-dependent individuals (CDs) and 122 healthy controls (HCs) in 2 separate cohorts...
August 14, 2023: International Journal of Neuropsychopharmacology
Szabolcs Koncz, Noémi Papp, Dóra Pothorszki, György Bagdy
BACKGROUND: Racemic ketamine consists of two enantiomers, namely (R)ketamine and (S)ketamine, with distinguishable pharmacological properties. Both enantiomers have been reported to show rapid antidepressant effects in rodents. Currently, the (S)enantiomer has been approved for the treatment of major depression, while (R)ketamine failed to show antidepressant effect in recent clinical studies. Major depressive disorder is frequently characterized by disinhibition of rapid eye movement (REM) sleep and disruption of nonREM (NREM) sleep...
August 14, 2023: International Journal of Neuropsychopharmacology
Sandra Ledesma-Corvi, M Julia García-Fuster
BACKGROUND: We recently showed sex differences in the antidepressant-like potential of electroconvulsive seizures (ECS) in adolescent rats; while it worked for male rats it rendered inefficacious in females. Since sex steroids might be important modulators of these sex disparities, we evaluated the role of estrogens in the differential response induced by adolescent ECS. Moreover, given the literature suggesting certain cognitive sequelae from ECS exposure, we aimed at evaluating its long-term safety profile in adulthood...
August 10, 2023: International Journal of Neuropsychopharmacology
Obed Okwoli Apochi
No abstract text is available yet for this article.
August 7, 2023: International Journal of Neuropsychopharmacology
Gunild M Vulpius, Kristin Köhler-Forsberg, Brice Ozenne, Søren V Larsen, Arafat Nasser, Claus Svarer, Nic Gillings, Sune H Keller, Martin B Jørgensen, Gitte M Knudsen, Vibe G Frokjaer
BACKGROUND: A prominent finding in Major Depressive Disorder (MDD) is distorted stress hormone dynamics, which is regulated by serotonergic brain signaling. An interesting feature of the cerebral serotonin system is the serotonin 4 receptor (5-HT4R), which is lower in depressed relative to healthy individuals, and also has been highlighted as a promising novel antidepressant target. Here, we test the novel hypothesis that brain 5-HT4R availability in untreated patients with MDD is correlated with cortisol dynamics, indexed by the cortisol awakening response (CAR)...
August 5, 2023: International Journal of Neuropsychopharmacology
Cary S Kogan, José A Garcia-Pacheco, Tahilia J Rebello, Madeline I Montoya, Rebeca Robles, Brigitte Khoury, Maya Kulygina, Chihiro Matsumoto, Jingjing Huang, María Elena Medina-Mora, Oye Gureje, Dan J Stein, Pratap Sharan, Wolfgang Gaebel, Shigenobu Kanba, Howard F Andrews, Michael C Roberts, Kathleen M Pike, Min Zhao, José Luis Ayuso, Karolina Sadowska, Karen Maré, Keith Denny, Geoffrey M Reed
BACKGROUND: Increased levels of occupational stress among health professionals during the COVID-19 pandemic have been documented. Few studies examined the effects of the pandemic on mental health professionals despite the heightened demand for their services. METHOD: A multilingual, longitudinal, global survey was conducted at three time points during the pandemic among members of the WHO's Global Clinical Practice Network (GCPN). 786 GCPN members from 86 countries responded to surveys assessing occupational distress, well-being and post-traumatic stress symptoms...
August 2, 2023: International Journal of Neuropsychopharmacology
Yuting Yang, Rui Chen, Caixia Li, Qingshan Zheng, Yinghua Lv, Lujin Li, Hongsheng Tan
BACKGROUND: Wendan decoction (WDD) has been used as a treatment for depression in China since the Tang Dynasty. However, high-quality evidence for this is lacking. This study proposed a novel synthetic external control method to evaluate its clinical efficacy. METHODS: Clinical trials of WDD for major depression were searched for using public databases. The rate of change of the Hamilton Depression Scale (HAMD) score from baseline was used as an efficacy indicator, and a model-based meta-analysis (MBMA) was performed to analyze the clinical efficacy of WDD...
July 26, 2023: International Journal of Neuropsychopharmacology
Wei-Chen Lin, Tung-Ping Su, Cheng-Ta Li, Hui-Ju Wu, Ya-Mei Bai, Yu-Li Liu, Pei-Chi Tu, Mu-Hong Chen
BACKGROUND: The role of neurofilament light chain (NFL) in treatment-resistant depression (TRD) is unclear. Whether baseline NFL concentrations are associated with the antidepressant effects of low-dose ketamine infusion has not been determined. METHODS: The NFL concentrations of 71 patients with TRD and 17 healthy controls were assessed. Patients with TRD were randomly administered a single infusion of 0.5 mg/kg ketamine, 0.2 mg/kg ketamine, or normal saline...
July 25, 2023: International Journal of Neuropsychopharmacology
Yi-Fan Cong, Fu-Wang Liu, Li Xu, Shuang-Shuang Song, Xu-Ri Shen, Dong Liu, Xue-Qin Hou, Han-Ting Zhang
BACKGROUND: Alzheimer's disease (AD) and depression often co-occur, and inhibition of phosphodiesterase-4 (PDE4) has been shown to ameliorate neurodegenerative illness. Therefore, we explored whether PDE4 inhibitor rolipram might also improve the symptoms of comorbid AD and depression. METHODS: APP/PS1/tau mice (10 months old) were treated with or without daily intraperitoneal injections of rolipram for 10 days. The animal groups were compared in behavioral tests related to learning, memory, anxiety, and depression...
July 25, 2023: International Journal of Neuropsychopharmacology
Denisse Paredes, David A Morilak
BACKGROUND: Post-traumatic stress disorder is characterized by deficits in cognitive flexibility related to dysfunction of the medial prefrontal cortex (mPFC). Exposure therapy can effectively reverse these deficits. Fear extinction in rodents bears similarity to exposure therapy. Extinction reverses chronic stress-induced deficits in cognitive flexibility on the attentional set-shifting test (AST), a mPFC-mediated process. This therapeutic effect requires activity of pyramidal neurons and BDNF signaling in infralimbic cortex (IL)...
July 22, 2023: International Journal of Neuropsychopharmacology
Dean Najarian, Ibrahim Turkoz, R Karl Knight, Silvana Galderisi, Hector F Lamaison, Piotr Zalitacz, Suresh Aravind, Ute Richarz
BACKGROUND: Paliperidone palmitate 6-month (PP6M) demonstrated noninferiority to paliperidone palmitate 3-month (PP3M) in preventing relapse in patients with schizophrenia in a phase-3 double-blind (DB) study (NCT03345342). Here, we report long-term efficacy and safety results from a 2-year single-arm, open-label extension (OLE; NCT04072575) of this DB study. METHODS: Participants who completed the DB study without relapse were enrolled and followed-up every 3 months up to 2 years...
July 22, 2023: International Journal of Neuropsychopharmacology
(no author information available yet)
No abstract text is available yet for this article.
July 11, 2023: International Journal of Neuropsychopharmacology
Chieh-Hsin Lin, Tin-May Li, Yu-Jhen Huang, Shaw-Ji Chen, Hsien-Yuan Lane
BACKGROUND: Impaired antioxidant defense is implicated in the pathophysiology of schizophrenia; and superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) are three first-line endogenous antioxidants. Various cognitive functions decline differently during schizophrenia course. The characteristic roles of the three antioxidants in clinical and cognitive profiles in acute and chronic phases of schizophrenia require study. METHODS: We recruited 311 patients with schizophrenia, including 92 acutely exacerbated patients who had been off antipsychotics for at least 2 weeks and 219 chronic patients who had been stable on medication for at least 2 months...
July 9, 2023: International Journal of Neuropsychopharmacology
Deniz Doruk Camsari, Charles P Lewis, Ayse Irem Sonmez, Can Ozger, Parmis Fatih, Deniz Yuruk, Julia Shekunov, Jennifer L Vande Voort, Paul E Croarkin
BACKGROUND: Implicit cognitive markers may assist with the prediction of suicidality beyond clinical risk factors. The aim of this study was to investigate neural correlates associated with Death/Suicide Implicit Association Test (DS-IAT) via event-related potentials (ERP) in suicidal adolescents. METHODS: Thirty inpatient adolescents with suicidal ideations and behaviors (SIBS), and thirty healthy controls from community were recruited. All participants underwent 64-channel electroencephalography, DS-IAT, and clinical assessments...
July 9, 2023: International Journal of Neuropsychopharmacology
Guliqiemu Aimaier, Kun Qian, Huateng Cao, Weifeng Peng, Zhe Zhang, Jing Ding, Xin Wang
BACKGROUND: Diminished heart rate variability (HRV) has been observed in epilepsy, especially in epilepsy with depressive disorders. However, the underlying mechanism remains elusive. METHODS: We studied HRV, spontaneous recurrent seizures (SRSs) and depression-like behaviors in different phases of pilocarpine-induced temporal lobe epilepsy (TLE) in mice. Single-cell RNA sequencing analysis was used to identify various nerve cell subsets in TLE mice with and without depression...
July 7, 2023: International Journal of Neuropsychopharmacology
Fumitoshi Kodaka, Kazutaka Ohi, Yuka Yasuda, Michiko Fujimoto, Hidenaga Yamamori, Naomi Hasegawa, Satsuki Ito, Kentaro Fukumoto, Junya Matsumoto, Kenichiro Miura, Norio Yasui-Furukori, Ryota Hashimoto
BACKGROUND: Clinician adherence to guideline recommendations in the pharmacological therapy of schizophrenia is important for favorable patient outcomes. To evaluate whether prescriptions followed the guidelines for pharmacological therapy of schizophrenia, we recently developed a summary indicator of multiple quality indicators: the individual fitness score (IFS). It is unclear whether adherence to the guidelines is related to patient outcomes. Here, we investigated correlations between the IFS values and psychotic symptoms in patients with schizophrenia...
June 29, 2023: International Journal of Neuropsychopharmacology
Berta Escudero, Marta Moya, Leticia López-Valencia, Francisco Arias, Laura Orio
BACKGROUND: Apolipoprotein E (APOE)-4 isoform, Reelin and Clusterin share VLDLR and APOER2 receptors and are related to cognition in neuropsychiatric disorders. These proteins are expressed in plasma and brain but studies involving plasma expression and cognition are scarce. METHODS: We studied the peripheral expression (plasma and PBMCs) of these proteins in 24 Alcohol Use Disorder (AUD)-diagnosed middle-aged subjects at 4-12 weeks of abstinence (t=0) and 34 controls...
June 23, 2023: International Journal of Neuropsychopharmacology
Ravi Anand, Alessio Turolla, Giovanni Chinellato, Arjun Roy, Richard D Hartman
No abstract text is available yet for this article.
June 22, 2023: International Journal of Neuropsychopharmacology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.